The company is also revamping and upgrading its Thrive, a natural nutritional supplement for fighting chronic metabolic disorders.

According to analysts, the markets are likely move in line with global markets in absence of triggers from domestic markets.

Indian markets are likely to trade in a range. Here is a list of ten stocks which are likely to be in focus in trade today.

Elder Pharmaceuticals has appointed consulting firm Deloitte for restructuring the company and its brands including ‘Eldervit’.

The firm plans to strengthen existing brands and aggressively tap the growing nutraceutical segment by launching more products.

Centrum initiates coverage on Elder Pharmaceuticals with a `Buy’ rating and a target price of Rs 487, valuing the stock at 9x FY12E earning...

Elder Pharmaceuticals is in talks with a clutch of private equity (PE) firms to raise Rs 125-150 crore for drug research, a manufacturing u...

Elder Pharmaceuticals has earmarked a Rs 40-crore investment for a rural thrust and set up a dedicated division called 'Elvista' to spread ...

Elder Pharmaceuticals is increasing its focus on the rural market.

Indian pharmaceutical companies with a presence in sterile injectables space are expanding capacities to cater to growing demand in this se...

CARE has reaffirmed 'PR1+' rating to the commercial paper programme of Elder Pharmaceuticals Ltd aggregating to Rs 75 crore.